Zymeworks Inc. (ZYME)

NASDAQ: ZYME · Real-Time Price · USD
12.57
0.00 (0.00%)
Aug 1, 2025, 4:00 PM - Market open
Market Cap940.80M
Revenue (ttm)93.38M
Net Income (ttm)-113.68M
Shares Out 74.84M
EPS (ttm)-1.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9
Open12.57
Previous Close12.57
Day's Range12.57 - 12.68
52-Week Range9.03 - 17.70
Beta1.26
AnalystsBuy
Price Target19.50 (+55.13%)
Earnings DateAug 7, 2025

About X

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprisin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2017
Employees 286
Stock Exchange NASDAQ
Ticker Symbol ZYME
Full Company Profile

Financial Performance

In 2024, Zymeworks's revenue was $76.30 million, an increase of 0.38% compared to the previous year's $76.01 million. Losses were -$122.70 million, 3.39% more than in 2023.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price target is $19.5, which is an increase of 55.13% from the latest price.

Price Target
$19.5
(55.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...

7 days ago - GlobeNewsWire

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...

18 days ago - GlobeNewsWire

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Ph...

7 weeks ago - Seeking Alpha

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...

2 months ago - GlobeNewsWire

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...

2 months ago - GlobeNewsWire

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...

2 months ago - GlobeNewsWire

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

VANCOUVER, British Columbia, May 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...

2 months ago - GlobeNewsWire

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore ...

3 months ago - Seeking Alpha

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...

3 months ago - GlobeNewsWire

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER...

3 months ago - Seeking Alpha

Zymeworks: Poised For Growth With Platform Validation

Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 ...

3 months ago - Seeking Alpha

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

3 months ago - GlobeNewsWire

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape...

3 months ago - GlobeNewsWire

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape...

3 months ago - GlobeNewsWire

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile

4 months ago - GlobeNewsWire

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.

5 months ago - Benzinga

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, ...

5 months ago - Seeking Alpha

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape...

5 months ago - GlobeNewsWire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...

5 months ago - GlobeNewsWire

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...

5 months ago - GlobeNewsWire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...

6 months ago - GlobeNewsWire

3 Biotech Stocks With Notable Insider Buying

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...

Other symbols: AUPHAZNCOGTJAZZONCXBI
6 months ago - Seeking Alpha

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...

7 months ago - GlobeNewsWire

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks ...

8 months ago - Seeking Alpha

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...

9 months ago - GlobeNewsWire